CMV Serostatus of Donor-Recipient Pairs Influences the Risk of CMV Infection/Reactivation in HSCT Patients
Table 5
Univariate analysis of risk factors for CMV reactivation/infection event(s) in group of SIB and MUD HLA match patients and in group of MUD HLA mismatch patients.
Optimally matched group (SIB+ 10/10 HLA matched) of patients
MUD HLA mismatched group of patients
Variable
CMV absence
CMV presence
value
CMV absence
CMV presence
value
Infection/reactivation until 1 year post HSCT
Infection/reactivation until 1 year post HSCT
Source of HSCT
PBPC
95
30
1.000
17
18
0.232
BM
18
6
3
0
Conditioning regimen
Absence of ATG and Campath
33
5
0.167
0.170
ATG
60
22
19
14
Campath
20
9
1
4
RIC
53
23
0.087
7
7
1.000
Myeloablative
60
13
13
11
Donor CMV IgG
CMV IgG−
26
12
0.273
10
11
0.532
CMV IgG+
86
24
10
7
Recipient CMV IgG
CMV IgG−
18
2
0.160
6
2
0.238
CMV IgG+
95
34
14
16
Donor-recipient IgG CMV serology
R−/D−
10
0
5
1
R−/D+
8
2
0.032
1
1
0.18
R+/D−
16
12
5
10
R+/D+
78
22
9
6
R−/D−, R−/D+, R+/D+
96
24
0.015
15
8
0.096
R+/D−
16
12
5
10
Donor/recipient gender
Male to male, female to female, and male to female
